Survival outcomes for patients with extensive stage small cell lung cancer (ES-SCLC) treated with consolidative thoracic radiation therapy (cTRT) and chemoimmunotherapy (CIT): A population level study ...

Several studies from different countries have been undertaken to investigate sarcoidosis with extrapulmonary involvement except from China. The objective of this study is to investigate a comparative ...

Background Extrapulmonary tuberculosis (EPTB) is a significant public health issue in Indonesia, a country with a high tuberculosis burden. EPTB accounts for 15%–20% of global TB cases, with the ...

Safety and efficacy of TQB2102, a novel bispecific anti-HER2 antibody–drug conjugate, in patients with advanced solid tumors: Preliminary data from the first-in-human phase 1 trial. [212Pb]VMT-α-NET ...

The smartphone-sized, battery-powered test is a cost-effective tool that can improve TB diagnoses, particularly in rural ...

Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs") today announced the presentation of groundbreaking clinical data from a multicenter phase Ib/II clinical trial evaluating LBL-024, an anti-PD-L1/4-1BB ...

Mammalian target of rapamycin (mTOR) inhibitors, such as sirolimus and everolimus, have recently become a treatment option for LAM patients, especially those with extrapulmonary manifestations. The ...

The following is a summary of “CD4/CD8 T-cell ratio in bronchoalveolar lavage fluid as a marker of sarcoidosis severity: a ...

In addition, new data evaluating the efficacy and safety of obrixtamig for the treatment of extrapulmonary neuroendocrine carcinomas with high or low DLL3 expression will be featured in an oral ...

The lungs are involved in 90% of cases. Extrapulmonary manifestations occur in 30%–50% of patients, most commonly affecting the skin, eyes, heart, liver and nervous system.1 The disease exhibits ...